Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1391.573
- -10.297-0.73%
Trading Nov 19 10:46 ET
1395.332High1383.814Low
1392.620Open1401.870Pre Close7.03MVolume4Rise69.88P/E (Static)228.38MTurnover--Flatline0.49%Turnover Ratio167.12BMarket Cap6Fall165.01BFloat Cap
Constituent Stocks: 10Top Rising: APLS+10.54%
Sign in to post a comment
$CRISPR Therapeutics (CRSP.US)$ everyday I get updates from Ark funds, and Cathy has been selling Tesla palantir and buying this stock in huge amounts. if you pull a multi-year chart you can see why she's doing it you don't even need to understand what the hell the company does but look at the band it's been trading in going back almost 3 years look where the current price is right now relative to the lower end of the band and look at the spikes that this stock has it's a 50% upside Gap from curr...
1
In the end, a week that starts with an all-time high for the S&P 500, Dow Jones, and Nasdaq 100, ended with equities lower.
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
68
15
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
You will not get through the trading day without the news and animal spirits guiding the market. It is finally Friday, November 15th.
My name is Kevin Travers and the market is falling today- here is why.
$Alibaba (BABA.US)$ shares declined after a report from the firm Friday morning that it was facing a consumer demand slump, even though its AI cloud business grew 7% to $4.2B in its second fiscal quarter.
$Applied Materials (AMAT.US)$ fell 8% after r...
My name is Kevin Travers and the market is falling today- here is why.
$Alibaba (BABA.US)$ shares declined after a report from the firm Friday morning that it was facing a consumer demand slump, even though its AI cloud business grew 7% to $4.2B in its second fiscal quarter.
$Applied Materials (AMAT.US)$ fell 8% after r...
25
6
$CRISPR Therapeutics (CRSP.US)$ Cathy Woods was just live on TV pumping this up this is one of her larger holdings she buys every single day now
3
3
$CRISPR Therapeutics (CRSP.US)$ yeah I'm out for now 😑
1
$CRISPR Therapeutics (CRSP.US)$ is this stock gonna do anything?🤔
1
1
$Sangamo Therapeutics (SGMO.US)$
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
S-3: Registration statement for specified transactions by certain issuers
“This registration statement contains two prospectuses:
•
a base prospectus, which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $500,000,000 of the registrant’s common stock, preferred stock, debt securities and/or warrants from time to time in one or more offerings; and
•
a sales agreement prospectus, which cov...
3
$Sangamo Therapeutics (SGMO.US)$ Third Quarter 2024 Financial Results
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.
Revenues
Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.
The increase of $40.0 millio...
2
5
$Sangamo Therapeutics (SGMO.US)$
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
This is the new medicine. Gene Therapies will save the heathcare systems of the world Trillions in the future.
Pfizer's Hemophilia B treatment already approved is just the beginning. GLTA.
"Internal CSL figures estimate that between annual bleed rates and required therapies to address hemophilia B, a patient with the disease can cost an insurer $20 million over the course of their life. That puts the expenditure of $3.5 million for a gene therapy to reverse or c...
1
No comment yet
Lnova : “you don’t even need to understand what the hell the company does”